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Recent reports have demonstrated that disruption of CB1 receptor signaling impairs extinction of learned responses in conditioned fear
and Morris water maze paradigms. Here, we test the hypothesis that elevating brain levels of the endogenous cannabinoid anandamide
through either genetic deletion or pharmacological inhibition of its primary catabolic enzyme fatty-acid amide hydrolase (FAAH) will
potentiate extinction in a fixed platform water maze task. FAAH ( / ) mice and mice treated with the FAAH inhibitor OL-135, did not
display any memory impairment or motor disruption, but did exhibit a significant increase in the rate of extinction. Unexpectedly, FAAH-
compromised mice also exhibited a significant increase in acquisition rate. The CB1 receptor antagonist SR141716 (rimonabant) when
given alone had no effects on acquisition, but disrupted extinction. Additionally, SR141716 blocked the effects of OL-135 on both
acquisition and extinction. Collectively, these results indicate that endogenous anandamide plays a facilitatory role in extinction through a
CB1 receptor mechanism of action. In contrast, the primary psychoactive constituent of marijuana, D
9-tetrahydrocannabinol, failed to
affect extinction rates, suggesting that FAAH is a more effective target than a direct acting CB1 receptor agonist in facilitating extinction.
More generally, these findings suggest that FAAH inhibition represents a promising pharmacological approach to treat psychopathologies
hallmarked by an inability to extinguish maladaptive behaviors, such as post-traumatic stress syndrome and obsessive-compulsive
disorder.
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INTRODUCTION
Behavioral extinction processes have been studied for
decades, and are widely understood to represent a distinct
form of inhibitory learning rather than an ‘unlearning’ of a
conditioned response (Rescorla, 2001). Pharmacological
manipulation of mechanisms underlying extinction has
been suggested as a potential treatment strategy for a
variety of behavioral disorders such as specific phobias,
post-traumatic stress disorder, and even drug abuse.
Extinction processes have been reportedly affected by a
variety of pharmacological agents, though the particular
mechanisms that trigger the initiation of extinction learning
are still largely unclear. For example, NMDA antagonists,
voltage-gated calcium channel blockers, benzodiazepines,
and dopaminergic modulators have all been reported to
disrupt extinction, whereas facilitation of extinction has
been observed with the partial NMDA agonist D-cyclo-
serine, and the GABAA antagonist picrotoxin (Myers and
Davis, 2002). Recently, both CB1 receptor ( / ) mice and
mice treated with the CB1 antagonist SR141716 (rimona-
bant) displayed impaired extinction in conditioned fear
tests (Marsicano et al, 2002; Suzuki et al, 2004), as well as in
the Morris water maze (Varvel et al, 2005a). Taken together,
the results of these studies support the hypothesis that the
endocannabinoid system participates in processes under-
lying extinction learning.
Recent years have seen great strides in the characteriza-
tion of the endocannabinoid system, composed of multiple
subtypes of receptor, endogenous ligands, and specific
inactivation mechanisms (Lambert and Fowler, 2005). This
endogenous system has been implicated in several physio-
logical functions including the modulation of pain
(Calignano et al, 1998; Richardson et al, 1998; Walker
et al, 1999), feeding (Di Marzo et al, 2001), drug dependence
(Ledent et al, 1999; Lichtman et al, 2001; Gonzalez et al,
2002), excitotoxicity (Marsicano et al, 2003), anxiety
(Kathuria et al, 2003), depression (Gobbi et al, 2005; Witkin
et al, 2005), and cognition (Terranova et al, 1996; Marsicano
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www.neuropsychopharmacology.orget al, 2002; Varvel et al, 2005a). Of particular interest has
been the discovery of fatty-acid amide hydrolase (FAAH),
an integral membrane enzyme that is primarily responsible
for the degradation of the endocannabinoid anandamide as
well as several non-cannabinoid fatty-acid amides (FAAs;
(Cravatt et al, 1996)). FAAH ( / ) mice have been shown
to possess quantities of anandamide and other FAAs (eg,
oleamide, PEA, OEA) in the brain and other areas more
than 10 times the levels seen in wild-type mice. Accordingly,
FAAH ( / ) mice represent a useful tool to evaluate the
physiological function of these lipid signaling molecules
(Cravatt et al, 2001; Clement et al, 2003). In addition to
displaying dramatically enhanced responses to intraperito-
neal injections of anandamide, FAAH ( / ) mice display
CB1 receptor mediated hypoalgesic responses to radiant
heat and inflammatory stimuli (Cravatt et al, 2001;
Lichtman et al, 2004b). In parallel with the transgenic
models, several pharmacological inhibitors of FAAH have
been developed and shown to elicit cannabinoid-receptor
mediated analgesia, notably reversible a-ketoheterocyle
inhibitors (eg, OL-135), and irreversible carbamate inhibi-
tors (eg, URB-597). URB-597 was shown to elicit a CB1
receptor-mediated hypoalgesic response in the hot plate test
(Kathuria et al, 2003) as well as a CB2 receptor mediated
anti-edema effect in the carrageenan test (Holt et al, 2005).
Similarly, OL-135 produced CB1 receptor mediated hypo-
algesic effects in several pain assays including tail immer-
sion, hot plate, and formalin tests (Lichtman et al, 2004a).
OL-135 has also been found to block mechanical allodynia
in a rat spinal nerve ligation model and this effect was
blocked with either the CB2 receptor antagonist SR144528
or naloxone, but not by SR141716 (Chang et al, 2006). On
the other hand, only naloxone blocked the allodynia in a
mild thermal injury rat model (Chang et al, 2006). Thus,
FAAH inhibitors have been demonstrated to decrease pain
sensitivity through CB1,C B 2, and opioid receptors.
Despite a growing consensus that the endocannabinoid
system modulates cognition, efforts to assess direct acting
cannabinoid agonists (eg, WIN55,212-2) on extinction are
confounded by the well-documented disruptive effects of
these agents on memory and locomotor behavior (Pamplona
and Takahashi, 2006). The availability of FAAH ( / ) mice
and selective FAAH inhibitors gives us the opportunity to
test for the first time whether increasing endogenous
anandamide levels will facilitate extinction without impair-
ing memory or causing motor disruption. We have recently
reported that FAAH ( / ) mice acquired a fixed-platform
water maze task normally, and displayed a slight, but
significant, enhancement in the acquisition of a repeated
acquisition (ie, working memory) task (Varvel et al, 2005b).
Another recent report showed that AM404, which inhibits
FAAH and is purportedly an inhibitor of the controversial
anandamide uptake transporter (Beltramo et al, 1997;
Jarrahian et al, 2000; Glaser et al, 2003; Hillard and
Jarrahian, 2005), enhanced the extinction of a fear-
potentiated startle response (Chhatwal et al, 2005). Thus
the present experiments were conducted to test the
hypothesis that elevating endogenous levels of anandamide
would enhance extinction. To this end, FAAH ( / ) mice
as well as mice treated with OL-135 were evaluated for
acquisition and extinction in a fixed-platform water maze
task. In addition, SR141716 was employed to assess whether
the effects of OL-135 were mediated through the CB1
receptor. In order to compare a direct acting cannabinoid
receptor agonist to mice with the FAAH ( / ) mice and
OL-135-treated wild-type mice, an additional group of wild-
type mice was treated with D
9-tetrahydrocananbinol (THC),
the primary psychoactive constituent present in marijuana,
and evaluated for extinction in the Morris water maze
extinction task. Here, we report that FAAH-compromised
mice, but not THC-treated mice, display a CB1 receptor-
mediated acceleration in extinction rates in the Morris
water maze.
MATERIALS AND METHODS
Subjects
Male C57BL/6 mice (Jackson Laboratories, Bar Harbor,
ME), congenic FAAH ( / ) mice, and offspring (ie, FAAH
+/+ mice) derived from C57BL/6 breeding pairs from the
Virginia Commonwealth University (VCU) vivarium served
as subjects. All subjects were 7–12 weeks of age at the start
of the study and were housed in a temperature-controlled
(20–221C) environment, with a 12-h light/dark cycle. Food
and water were available ad libitum in the home cages. All
experiments were approved by the Institutional Animal
Care and Use Committee at VCU.
Apparatus
The water maze consisted of a large circular galvanized steel
pool (1.8m diameter, 0.6m height). A white platform (10cm
diameter) was placed inside, and the tank was filled with
water (221C) until the top of the platform was submerged
1cm below the water’s surface. A sufficient amount of white
paint (Proline-Latex Flat) was added to make the water
opaque and render the platform virtually invisible. An
automated tracking system (Columbus Instruments,
Columbus, OH) analyzed the swim path of each subject
and calculated several corresponding dependent measuresF
escape latencies (the time between being placed in the water
and finding the hidden platform), total path lengths,
average swim speeds, degree of thigmotaxia (percentage of
time spent in periphery of the pool), percent of time spent
in the target quadrant, and the number of entries into
specified target areas.
Drugs
THC and SR141716 were provided by the National Institute
on Drug Abuse (Bethesda, MD). We selected the reversible
inhibitor OL-135 because it is both highly selective for
inhibiting FAAH and active in vivo (Lichtman et al, 2004a).
In contrast, URB597 binds irreversibly to FAAH and AM404
is not selective. OL-135 was synthesized as described
previously (Boger et al, 2005). All drugs were dissolved
in a 1:1 mixture of absolute ethanol and alkamuls-620
(Rhone-Poulenc, Princeton, NJ) and diluted with saline
to a final ratio of 1:1:18 (ethanol:alkamuls:saline). Drug
injections were administered i.p. at an injection volume
of 10ml/kg.
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FAAH (+/+) and ( / ) mice in acquisition and
extinction. FAAH (+/+) and ( / ) mice were trained to
acquire a fixed-platform water maze task using procedures
identical to those previously described (Varvel and
Lichtman, 2002; Varvel et al, 2005b), except that a platform
location near the ‘back’ of the tank (ie, furthest from where
the experimenter enters and exits the tank area) was chosen.
Briefly, each subject was given a single 5-min acclimation
trial, in which it was placed in the tank with no platform
present. The first minute of this acclimation trial was
analyzed separately and used as a baseline measure for the
subsequent probe trials evaluated in the extinction phase of
the experiment. Mice then received a total of eight
acquisition sessions in which the hidden platform remained
in a fixed location. All sessions took place between Monday
and Friday, with the first acquisition session given on
Monday, Tuesday, or Wednesday, but never given on a
Thursday or Friday. Consequently, the last acquisition
session and the extinction sessions were never given
on a Monday. Each session consisted of four 2-min trials
with a 10min inter-trial interval. Mice were released into the
tank from a different position each trial (one of four
positions) in an attempt to minimize the use of non-spatial
strategies. The day following the final acquisition session
the platform was removed from the tank and mice were
assessed with a 60s probe trial (the first extinction trial).
The mice were then given a weekly 60-s trial for a total of 4
weeks. In order to control for the possibility that memory
duration is decreased in FAAH ( / ) mice compared with
the wild-type mice, a group (n¼6) of the FAAH ( / ) were
not given the first three extinction trials and were assessed
for the first time 3 weeks after completing acquisition
training.
OL-135 and SR141716 in acquisition and extinction.
Acquisition and extinction procedures used to evaluate
the effects of the FAAH inhibitor OL-135 were identical
to those described above except that mice received daily
one of four drug treatments vehicle+vehicle (N¼10),
vehicle+30mg/kg OL-135 (N¼11), 3mg/kg SR141716+
vehicle (N¼9), and 3mg/kg SR141716+30mg/kg
OL-135 (N¼10), 30min before each acquisition session
and each extinction trial. In an effort to delineate the
effects of FAAH inhibition between acquisition and
extinction, a follow-up experiment was conducted in which
OL-135 was only administered before each extinction
session.
Additional mice were trained to locate the platform using
identical procedures as described above except that no
drug treatments were administered during acquisition. The
day following the last acquisition session mice were treated
with vehicle (N¼8) or 30mg/kg OL-135 (N¼8) and
evaluated in a 60s probe trial, and this process was repeated
a week later. In order to distinguish between effects of
OL-135 on extinction vs forgetting, a third group (N¼6)
was simultaneously trained under the same acquisition
protocol and the next day was administered 30mg/kg OL-
135 in their home cages (no probe trial). The following week
they received a second injection of OL-135 and were
assessed with a probe trial.
Effects of THC on extinction. Naive C57BL/6 mice received
a 5-min acclimation and eight acquisition sessions as
described above. The day following the last acquisition
session, each mouse was treated with vehicle or THC (0.1,
0.3, 1, or 10mg/kg) and 30min later evaluated in a 60s
probe trial (N¼7 or 8 mice per treatment condition).
Subjects were then given the same treatment on four
additional weekly 60s extinction trials.
Statistical Analysis
The dependent measures of interest for acquisition were
escape latency (ie, latency to target) and path length to
target. In the extinction tests, we recorded the latencies and
path lengths to target as well as the percentage of time that
the mice swam in the target quadrant. All experiments were
analyzed with two-way (genotype by session or THC by
session) or three-way (OL-135 by SR141716 by session or
trial) ANOVAs. The Newman–Keuls test was used to
compare effects of genotype or drug at each session to the
appropriate controls. Additional analyses of the extinction
data determined differences from the first extinction trial
for each group using Dunnett’s test. Significant differences
for all analyses were defined as po0.05.
RESULTS
FAAH ( / ) Mice Exhibit Facilitated Rates of Both
Acquisition and Extinction in the Morris Water Maze
Careful attention was paid to the general behavior of the
FAAH ( / ) mice throughout these experiments, and in
general they appeared identical to wild-type mice (eg, body
weight and home cage behavior). In particular, immediate
responses to being placed in the water and overall
swimming behavior appeared indistinguishable from wild-
type mice. As shown in Figure 1, FAAH ( / ) mice
acquired the fixed-platform task more quickly than did
Figure 1 FAAH ( / ) mice show enhanced acquisition rates in a fixed-
platform task. Escape latencies (s) are presented in (a), corresponding path
lengths (cm) are shown in (b). Asterisks represent significant differences
between genotypes at a given trial, *po0.05, ***po0.001. The data
for each session represents the average of four daily trials7SEM. N¼11
(+/+) mice and 16 ( / ) mice.
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interaction was found for escape latencies (Figure 1a,
F(7,175)¼2.3, po0.05), and post hoc comparisons
(Newman–Keuls test) showed that FAAH ( / ) mice
found the platform faster than FAAH (+/+) mice on
sessions two (po0.05) and three (po0.001). A main effect
of genotype was also found on path lengths (Figure 1b,
F(7,175)¼6.9, po0.05), where the distance swum by FAAH
( / ) mice was shorter than FAAH (+/+)miceonsession
three (po0.001). An effect of genotype was also found for
swim speeds, F(7,175)¼7.6, po0.05, with FAAH ( / )
mice swimming faster on sessions two through four than
FAAH (+/+) mice (po0.05, data not shown).
As shown in Figure 2, FAAH ( / ) mice also extin-
guished this learned response at a quicker rate than FAAH
(+/+)mice.Effects of genotype were found for latency to
target (Figure 2a, F(1,85)¼16.0, po0.001), path length to
target (Figure 2b, F(1,85)¼34.3, po0.001), and percent of
time spent in the target quadrant (Figure 2c, F(1,85)¼5.8,
po0.05). In contrast, no significant effects were found for
swim speed. Post hoc comparisons examining the effect of
genotype at each session revealed that FAAH ( / ) mice
had longer path lengths to target on the third (po0.05) and
fifth (po0.05) extinction trials than those of FAAH (+/+)
mice. A similar trend was noticed for the latency to
target measure, though differences on the third extinction
trial only approached significance (p¼0.06). The percen-
tage of time spent in the target quadrant was reduced
in FAAH ( / ) mice on extinction trials 3 and 4
compared with wild-type mice (po0.05). A similar pattern
of results was obtained when Dunnett’s tests were used to
identify differences from the first extinction trial for each
group. In FAAH (+/+) mice, latencies and path lengths
were only different on the fifth (final) trial, whereas
the percentage of time in the target quadrant never
significantly differed from the first extinction trial. In
contrast, FAAH ( / ) mice had longer latencies and less
time in the target quadrant on trials 3–5, and higher path
lengths on the fourth and fifth trials compared to the first
extinction trial. Direct comparisons were made between the
FAAH ( / ) group that received three extinction sessions
(Group FAAH ( / ) Extinction) and the FAAH ( / ) mice
that were not given any extinction trials until 3 weeks after
the last day of acquisition (Group FAAH ( / )N o
Extinction). Group FAAH ( / ) Extinction had longer
latencies (Figure 2a, po0.05), longer path lengths
(Figure 2b, po0.05), and spent less time in the correct
quadrant (Figure 2c, po0.05) than did group FAAH ( / )
No Extinction. These findings indicate that that FAAH
( / ) mice exhibited facilitated extinction as opposed to
impaired memory duration.
Effects of OL-135 and SR141716 in Acquisition and
Extinction Tasks
The effects of OL-135 and SR141716 pretreatment on
escape latency and path length to target on acquisition
of the fixed platform task are presented in Figure 3. A
main effect on distance swum was found for OL-135
treatment, F(1,252)¼4.3, po0.05, but not for SR141716,
F(1,252)¼0.30, p¼0.59. Post hoc comparisons revealed
that path lengths in the OL-135 treatment group were
shorter than in the vehicle group on the second and sixth
acquisition sessions (po0.05). Furthermore, the SR141716
+OL-135 group had longer path lengths when compared to
the OL-135 group on the second and third acquisition
sessions (po0.05), demonstrating that this effect of OL-135
was prevented by SR141716 treatment. Although a similar
trend was observed in the escape latency data (Figure 3a),
the main effects of OL-135 (p¼0.11) and SR141716
treatment (p¼0.54) failed to achieve statistical significance.
There were also no effects of OL-135 treatment on
swim speeds (data not shown), F(1,252)¼0.67, p¼0.66.
In contrast, SR141716 significantly increased speeds,
Figure 2 FAAH ( / ) mice show enhanced extinction compared to FAAH (+/+) mice. Latencies (s) to reach where the platform had been located
are presented in (a), corresponding path lengths to target (cm) are shown in (b), and the percentage of time spent in the target quadrant is presented in (c)
(dotted line from the 25% point of the ordinate spanning the width of the abscissa indicates chance performance). The first probe trial was conducted before
acquisition (baseline), subsequent extinction trials were conducted the day after the last acquisition session and once per week after that. Asterisks represent
significant differences between genotypes at a given trial, *po0.05, stars ($) represent significant differences between FAAH ( / ) mice and the FAAH
( / ) control group on extinction trial 4, po0.05. All data are represented as mean7SEM. N¼9 (+/+) mice, 10 ( / ) mice, and 6 ( / ) control mice.
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faster than the vehicle group on the first, third, and fourth
sessions (po0.05).
Results from the extinction experiment showed that
OL-135 also enhanced extinction rates, and that SR141716
blocked these effects and disrupted extinction when given
alone for each of the dependent measures (ie, latency, path
length, and quadrant data; see Figure 4). A three-way
ANOVA conducted on the extinction trial latencies to target
(Figure 4a) revealed main effects of OL-135, F(1,192)¼5.7,
po0.05, SR141716, F(1,192)¼13.0, po0.01, and trial,
F(6,192)¼18.4, po0.001. However, no significant effects
were found for swim speed. Post hoc comparisons revealed
that latency to target was longer in the OL-135 group
compared to vehicle on the second extinction trial
(po0.05), and that this effect was prevented by co-
treatment with SR141716 (po0.05). SR141716 by itself
produced opposite effects of OL-135, as this group had
faster latencies to target compared to vehicle on the fourth
extinction trial (po0.05). Similar results were found for
path length to target data (Figure 4b), where main effects
were found for OL-135, F(1,192)¼4.2, po0.05, and
SR141716, F(1,192)¼5.8, po0.05. OL-135-treated mice
had longer path lengths on the second extinction trial
compared to vehicle-treated (po0.05) or OL-135+
SR141716-treated mice (po0.05). Analysis of the percent
of time spent in the target quadrant (see Figure 4c) failed to
reveal significant effects of OL-135, F(1,192)¼2.0, p¼0.17,
though there were significant effects of SR141716,
F(1,192)¼6.7, po0.05, and session, F(6,192)¼14.3,
po0.001. Dunnett’s tests conducted for each group to
identify differences from the first extinction trial found
that the vehicle-treated group had increases in both
latency to target and path length to target on trials 4–6,
and spent less time in the target quadrant only on the fourth
trial. Supporting the interpretation of facilitated extinction,
the OL-135-treated group displayed significantly longer
latencies and longer path lengths on trials 2–6 than on
trial 1. Similarly, these mice spent less time in the
target quadrant on trials 4–6 than trial 1. The opposite
effect was observed in the SR141716-treated mice,
as no extinction trials differed from the first on any
Figure 4 Effects of daily treatments with 30mg/kg OL-135, 3mg/kg SR, or the combination of both on a delayed extinction task. Latencies (s) to reach
where the platform had been located are presented in the (a), corresponding path lengths to target are shown in (b), and the percentage of time spent in
the correct quadrant is presented in (c) (dotted line from the 25% point of the ordinate spanning the width of the abscissa indicates chance performance).
Asterisks represent significant differences between the veh+veh and OL-135+veh, *po0.05. Stars ($) represent significant differences between the OL-
135+veh and OL-135+SR141716 groups, po0.05. Pound signs (#) represent differences between the veh+veh and veh+SR141716 groups, po0.05.
Post hoc comparison of each extinction trial compared to the first extinction trial for each respective group can be found in the text. All data are represented
as mean7SEM. N¼7–11 mice per group.
Figure 3 Effects of daily treatments with 30mg/kg OL-135, 3mg/kg
SR141716, or the combination of both on acquisition of a standard water
maze task. Escape latencies (s) are presented in (a), corresponding path
lengths (cm) in (b). The data for each session represents the average of
four daily trials7SEM. Asterisks represent significant differences between
the veh+veh group and the OL-135+veh group, *po0.05. Stars ($)
represent significant differences between the OL-135+veh and OL-135+
SR141716 groups, po0.05. N¼7–11 mice per group.
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SR141716 alone group in that the latency to target
measure for both of these groups was significantly increased
only on the sixth extinction trial, and no differences were
observed on path lengths or time spent in the target
quadrant.
OL-135 Given Only before Extinction Trials
The effects of OL-135 given before the extinction probes and
not during acquisition are presented in Figure 5, and swim
traces of a representative mouse from each treatment
group are shown in Figure 6. Escape latencies (Figure 5a,
F(1,28)¼17.9, po0.001) path lengths (Figure 5b,
F(1,28)¼10.0, po0.01) and time in the correct quadrant,
F(1,28)¼6.9, po0.05, were all affected by OL-135 treat-
ment. Post hoc comparisons revealed that the OL-135-
treated group had longer latencies and path lengths on the
third probe (ie, second extinction trial) than did vehicle-
treated mice (po0.05), however, the quadrant data failed to
achieve significance on this second extinction probe.
Further analysis of the quadrant data showed that whereas
there was a significant decrease in the time spent in the
target quadrant between the first and second extinction trial
for the OL-135 group (po0.05), the vehicle group did not
change. Direct comparisons between the OL-135-treated
group that received a previous extinction session and the
OL-135-treated group that received only a single probe trial
1 week after acquisition revealed differences in latency to
the target location (Figure 5a, po0.05) and path lengths
(Figure 5b, po0.05), but not time spent in the target
quadrant, indicating that OL-135 specifically facilitated
extinction rates and did not have any apparent effects on
forgetting following the passage of time.
THC Fails to Affect Extinction
As shown in Figure 7, THC failed to have any significant
effects on the latency to target location, path length to target
location, and time spent in the quadrant that the target had
previously been located. For each dependent measure, a
significant repeated measures effect was found for probe
session (po0.001), indicating that the groups underwent
extinction across the 5 weekly probe trials. However, the
main effect of THC as well as the THC by probe interaction
failed to achieve significance for each of the three dependent
measures.
DISCUSSION
The results of the present study demonstrate for the first
time that elevating brain levels of FAAs, including the
endogenous cannabinoid anandamide, via either genetic
deletion or pharmacological inhibition of FAAH facilitated
the extinction of a spatial memory task. These findings
support the hypothesis that the endocannabinoid system
plays an important role in modulating extinction learning
(Marsicano et al, 2002; Suzuki et al, 2004; Varvel et al,
2005a). In contrast, a wide dose range of THC failed to have
any significant effects on extinction. An unexpected finding
was that both the FAAH ( / ) mice and mice treated with
the FAAH inhibitor OL-135 acquired the hidden platform
task faster than their respective controls. The effects of
OL-135 on both acquisition and extinction were reversed by
SR141716, implicating a CB1 receptor mechanism of action.
Importantly, the effects of FAAH deletion and FAAH
inhibition on extinction were distinguished from effects
on forgetting, as the experience of non-reinforced trials was
necessary to observe this effect.
Figure 5 OL-135 (30mg/kg) accelerates extinction rate when administered only before each extinction trial. In contrast, a control group that received
OL-135 in their home cages the day after acquisition training but were not given their first probe (ie, extinction) trial until 8 days later exhibited near perfect
performance, indicating that OL-135 per se did not simply result in forgetting. Latencies (ss) to enter the location where the platform had been previously
situated are presented in the (a), corresponding path lengths to target are shown in (b), and the percentage of time spent in the correct quadrant is
presented in (c) (dotted line from the 25% point of the ordinate spanning the width of the abscissa indicates chance performance). Asterisks (*) represent
significant differences (po0.05) between vehicle (N¼8 mice) and OL-135- (N¼8 mice) treated groups. Stars ($) represent significant differences
(po0.05) between the OL-135-treated group that received one extinction trial and the OL-135-treated group that received two extinction trials. All data
are represented as mean7SEM (N¼6 mice).
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FAAH ( / ) mice and C57BL/6 mice treated with OL-135
exhibited accelerated extinction rates of learned spatial
behavior compared to their respective controls. This effect
was dramatically evident on the second extinction trial in
the OL-135-treated mice, suggesting that a single extinction
trial in the presence of elevated FAAs was sufficient to
extinguish the learned response. The initial FAAH ( / )
and OL-135 experiments were incapable of distinguishing
whether it was necessary that FAAH be suppressed during
both acquisition and extinction phases because anandamide
and other FAAs levels were elevated throughout both
phases. Consequently, we evaluated whether OL-135 admi-
nistered only before each extinction trial would facilitate
Figure 6 Swim traces of representative mice in each treatment condition from the experiment presented in Figure 5.
Figure 7 Repeated i.p. injections of THC given 30min before each extinction probe trial failed to affect latency to target (a), path length to target (b), and
percentage of time spent in the target quadrant (c). The dotted line from the 25% point of the ordinate spanning the width of the abscissa in (c) indicates
chance performance). All data are represented as mean7SEM (N¼7–8 mice/group).
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only required during the extinction trials themselves. This
effect is consistent with a recent report in which AM404, a
purported inhibitor of the putative anandamide transporter
that also inhibits FAAH (Beltramo et al, 1997; Jarrahian
et al, 2000; Glaser et al, 2003; Hillard and Jarrahian, 2005)
potentiated extinction of a conditioned fear response
(startle) in rats (Chhatwal et al, 2005).
In the present study, OL-135-induced acceleration of
extinction was prevented by pretreatment with SR141716,
suggesting a CB1 receptor mechanism of action. However
this interpretation is somewhat limited by the fact that
SR141716 given alone delayed extinction. As previously
described in a similar water maze task (Varvel et al,
2005a) and in conditioned fear paradigms (Marsicano
et al, 2002; Suzuki et al, 2004; Chhatwal et al, 2005),
SR141716 robustly attenuated extinction in the present
experiment. The effect of SR141716 presented here repli-
cates our previously published report, with some minor
procedural differences such as the weekly extinction trials
(as opposed to bi-weekly trials) and the inclusion of the
quadrant data.
Taken together, the ability to increase or decrease
extinction rates, respectively, through the enhancement or
attenuation of endocannabinoid receptor signaling strongly
suggests a physiological role for the endocannabinoid
system in modulating extinction. It is noteworthy that
Marsicano et al (2002) found elevated levels of anandamide
and 2-AG in the amygdala of mice undergoing extinction in
the conditioned freezing task, suggesting that experiencing
non-reinforced trials increases the production and/or
release of endocannabinoids. Consistent with the notion
that the endocannabinoid system plays an integral role in
mnemonic processes, electrophysiological studies have
demonstrated that endocannabinoids are required for
certain forms of synaptic plasticity, such as long-term
depression in several brain regions (Gerdeman et al, 2002;
Hoffman et al, 2003; Huang et al, 2003; Robbe et al, 2003).
The facilitation of acquisition and extinction in FAAH
( / ) mice and OL-135-treated mice reported here
provides a dramatic example of how manipulations that
elevate endogenous compounds can lead to qualitatively
different results compared to exogenous administration of
direct-acting receptor agonists. THC (0.1–10mg/kg) failed
to affect performance during the first post-acquisition
probe trial. Similarly, we have previously reported that
mice that are given extensive training in a fixed platform
task are relatively impervious to the memory disruptive
effects of THC as well as the muscarinic antagonists
scopolamine (Varvel et al, 2001). On the other hand,
cannabinoid agonists have been demonstrated to impair
acquisition of the fixed-platform water maze task (Ferrari
et al, 1999; da Silva and Takahashi, 2002). Similarly, we have
found that cannabinoid receptor agonists consistently
impair performance in a working memory version of the
Morris water maze in which the location of the platform is
changed before each session (Varvel et al, 2001, 2005b;
Varvel and Lichtman, 2002). However, here we show that
THC given before each of the five post-acquisition probe
trials failed to have any significant effects on extinction.
Thus, the stimulation of CB1 receptors through either
direct-acting agonists or elevating endogenous levels of
anandamide leads to a strikingly distinct pattern of effects
in this spatial task.
The results with the FAAH ( / ) mice reported here
contrast with previous findings from our lab in which
FAAH ( / ) mice acquired the fixed platform task
identically to their wild-type control littermates (Varvel
et al, 2005b). A potentially relevant procedural difference
between our current and previous studies is the location of
the hidden platform. In the previous studies, the hidden
platform was arbitrarily placed towards the front of the tank
(ie, closest to where the experimenter entered and exited the
maze enclosure). However, in the present study, the
platform was moved to the ‘back’ of the tank (ie, furthest
from where the experimenter entered and exited the maze
enclosure), in order to utilize the computer software for
quantifying the percentage of time subjects spent in the
target quadrant. The new platform location appears to have
led to a slower acquisition rate in control animals compared
to the rather steep curves generated when the platform was
located in the ‘front’ of the tank. Consequently, the rapid
rate of acquisition in our previous studies precluded the
possibility of detecting any enhancement in FAAH ( / )
mice. However, by changing the platform location in the
present study, we appear to have inadvertently unmasked a
phenotypic enhancement in acquisition. A similar modest
enhancement of acquisition was observed in OL-135-treated
mice. The finding that SR141716 blocked this effect
indicates a CB1 receptor mechanism, and accordingly
implicates the involvement of anandamide, as anandamide
is the only known FAAH substrate with relevant CB1
receptor agonist activity.
The enhanced acquisition rate caused by stimulating the
endocannabinoid system was an unexpected and unique
observation. Interestingly, recent work has shown that
mature, but not young, CB1 receptor ( / ) mice display
cognitive deficits resembling those seen in aged (+/+)
mice, suggesting that the endocannabinoid system may
serve to protect against age-related cognitive decline
(Bilkei-Gorzo et al, 2005). Collectively, these results raise
the provocative possibility that facilitation of the endo-
cannabinoid system may represent a novel target for
nootropic activity. Alternatively, the enhanced acquisition
rates seen in the present study may be related to alterations
in emotional responding, rather than an effect on cognition.
Specifically, as carbamate FAAH inhibitors have been
shown to possess anxiolytic activity in the elevated zero
maze and isolation-induced vocalization assays in rats
(Kathuria et al, 2003), it is plausible that the enhanced
acquisition in the present study was a result of reduced
stress during the initial sessions. Nonetheless, the lack of
effect on thigmotaxia (considered a measure of anxiety) in
the present study (data not shown) is not consistent with
explanations of anxiolysis.
A pharmacological approach to facilitate extinction
learning has the potential to provide clinical benefits for
the treatment of phobias and related anxiety disorders. For
example, post-traumatic stress disorder is believed to be
due to impaired extinction of normal responses to trauma
(eg, re-experiencing, avoidance, and hyper-arousal), which
continue to be elicited by trauma-related cues long after the
traumatic event (Rothbaum and Davis, 2003). Support of
this extinction deficit model of PTSD comes from clinical
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related cues in a safe environment (ie, extinction training)
is the most empirically validated treatment of PTSD
(Rothbaum et al, 2000). The concept of combining
pharmacological strategies with behavioral exposure ther-
apy to treat anxiety disorders has recently been validated by
a study that demonstrated superior benefits of combined
treatment with the NMDA partial agonist D-cycloserine,
which has been shown to facilitate extinction of conditioned
fear in rats (Walker et al, 2002), with psychotherapy to treat
patients diagnosed with acrophobia (Ressler et al, 2004).
The lack of any apparent untoward phenotypes in FAAH
( / ) mice or animals treated with FAAH inhibitors
further supports the notion that FAAH inhibition represents
a particularly desirable therapeutic target.
In conclusion, the results of the present study indicate
that the endogenous cannabinoid system may play a
relevant role in facilitating extinction processes in the
Morris water maze task. These processes can be enhanced
or retarded through blockade of FAAH or the disruption of
CB1 receptors, respectively. The pharmacological potentia-
tion of extinction learning by inhibitors of FAAH may
prove particularly useful in conjunction with behavioral
exposure therapy in the treatment of a variety of psycho-
pathologies such as post-traumatic stress syndrome, which
are hallmarked by an inability to extinguish maladaptive
behaviors.
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